









Markets
/
Stocks
/
nasdaq-irwd
/

Ironwood Pharmaceuticals Inc

IRWD

1.460USD

+0.180+14.06%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

237.15MMarket Cap

LossP/E TTM



Ironwood Pharmaceuticals Inc

1.460

+0.180+14.06%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

81 / 175

Overall Ranking

219 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Hold

Current Rating

0.950

Target Price

-26.92%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 880.00K.%!(EXTRA int=2)

Undervalued

The company’s latest PE is -26.55, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 167.85M shares, decreasing 16.24% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 15.62M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 8.16, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 85.24M, representing a year-over-year decrease of 9.70%, while its net profit experienced a year-over-year decrease of 2844.07%.

Score

Industry at a Glance

Previous score

8.16

Change



Financials

6.72

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.40

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.67

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -26.55, which is -1110.05% below the recent high of 268.17 and 44.20% above the recent low of -14.82.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 81/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 6.00, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Ironwood Pharmaceuticals Inc is 1.00, with a high of 1.10 and a low of 0.70.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Hold

Current Rating

0.950

Target Price

-25.78%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Ironwood Pharmaceuticals Inc

IRWD

Biogen Inc

BIIB

Amgen Inc

AMGN

Alnylam Pharmaceuticals Inc

ALNY

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.25, which is lower than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 1.43 and the support level at 1.07, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.45

Change

-0.2

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.012

Buy

RSI(14)

69.820

Neutral

STOCH(KDJ)(9,3,3)

90.413

Overbought

ATR(14)

0.099

High Vlolatility

CCI(14)

132.238

Buy

Williams %R

0.000

Overbought

TRIX(12,20)

0.937

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

1.326

Buy

MA10

1.242

Buy

MA20

1.248

Buy

MA50

1.015

Buy

MA100

0.862

Buy

MA200

1.661

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 103.73%, representing a quarter-over-quarter increase of 2.98%. The largest institutional shareholder is The Vanguard, holding a total of 15.62M shares, representing 9.61% of shares outstanding, with 20.22% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Armistice Capital LLC

13.70M

+44.70%

Sarissa Capital Management, L.P.

16.39M

The Vanguard Group, Inc.

Star Investors

16.20M

+6.55%

BlackRock Institutional Trust Company, N.A.

10.76M

-49.54%

Renaissance Technologies LLC

Star Investors

9.94M

+9.64%

Acadian Asset Management LLC

2.65M

+160.75%

AQR Capital Management, LLC

2.52M

+535.76%

Two Sigma Investments, LP

3.11M

+48.36%

Kynam Capital Management LP

5.82M

+24.27%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 2.97, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.